NuCana plc Secures New US Patent for ProTide Technology
Ticker: NCNA · Form: 6-K · Filed: Sep 26, 2024 · CIK: 1709626
| Field | Detail |
|---|---|
| Company | Nucana PLC (NCNA) |
| Form Type | 6-K |
| Filed Date | Sep 26, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: patent, intellectual-property, pharmaceuticals
TL;DR
NuCana just got a new US patent for their ProTide tech, strengthening their IP for cancer drugs.
AI Summary
NuCana plc announced on September 25, 2024, that it has been issued a new patent (US12,0) for its ProTide technology. This patent is expected to strengthen the company's intellectual property portfolio related to its cancer treatments.
Why It Matters
The issuance of this patent reinforces NuCana's intellectual property rights, potentially enhancing its competitive position and future commercialization prospects for its novel cancer therapies.
Risk Assessment
Risk Level: low — This filing is a routine announcement of a patent issuance, which is generally positive and does not introduce new immediate risks.
Key Players & Entities
- NuCana plc (company) — The company issuing the press release and patent.
- US12,0 (patent) — The newly issued patent number.
- September 25, 2024 (date) — The date of the press release announcement.
FAQ
What is the specific title or subject of the newly issued US patent?
The filing states the patent is for NuCana's ProTide technology, but the specific title is not provided in this excerpt.
What is the expiration date of this new US patent?
The expiration date of the patent is not mentioned in this filing.
Does this patent cover specific drug candidates or the general ProTide technology?
The filing indicates the patent is for its ProTide technology, suggesting broader coverage, but specific drug candidates are not detailed.
What is the geographical scope of this new patent protection?
The filing explicitly mentions it is a US patent (US12,0), indicating protection within the United States.
When was the patent application filed?
The filing date of the patent application is not provided in this document.
Filing Stats: 403 words · 2 min read · ~1 pages · Grade level 15.5 · Accepted 2024-09-26 06:04:25
Filing Documents
- d823168d6k.htm (6-K) — 10KB
- d823168dex991.htm (EX-99.1) — 10KB
- 0001193125-24-226432.txt ( ) — 21KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NuCana plc By: /s/ Donald Munoz Name: Donald Munoz Title: Chief Financial Officer Date: September 26, 2024